Description |
RIPK2-IN-2 (example 25) is a RIP2 kinase PROTAC inhibitor. RIPK2-IN-2 can block RIP2-dependent proinflammatory signaling, regulated RIP2 kinase activity in auto inflammatory diseases[1].
|
Related Catalog |
|
In Vitro |
RIPK2-IN-2 (example 25) can simultaneously bind RIP2 kinase and an E3 ubiquitin ligase (VHL), which promotes ubiquitination of RIP2 Kinase and leads to RIP2 kinase degradation by the proteasome. through proteolysis targeting chimeric molecules PROTACs technology, RIPK2-IN-2 (example 25) can promotes ubiquitination of RIP2 Kinaseand degrade RIP2 kinase with the concentrations of RIPK2-IN-2﹤1 μM[1]. Western Blot Analysis[1] Cell Line: THP1 cells Concentration: ﹤1 μM Incubation Time: 12 h Result: Displayed > 80% degradation of RIP2 at concentrations ﹤1 μM.
|
References |
[1]. Conjugates comprising ripk2 inhibitors, WO2017182418 (example 25)
|